Cue Biopharma Statistics
Total Valuation
Cue Biopharma has a market cap or net worth of $27.11 million. The enterprise value is $12.86 million.
Important Dates
The next estimated earnings date is Monday, March 30, 2026, after market close.
| Earnings Date | Mar 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cue Biopharma has 91.24 million shares outstanding. The number of shares has increased by 74.30% in one year.
| Current Share Class | 91.24M |
| Shares Outstanding | 91.24M |
| Shares Change (YoY) | +74.30% |
| Shares Change (QoQ) | +5.67% |
| Owned by Insiders (%) | 0.65% |
| Owned by Institutions (%) | 25.10% |
| Float | 90.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.82 |
| Forward PS | 2.68 |
| PB Ratio | 1.74 |
| P/TBV Ratio | 2.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.47.
| Current Ratio | 1.66 |
| Quick Ratio | 1.46 |
| Debt / Equity | 0.47 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -83.02 |
Financial Efficiency
Return on equity (ROE) is -195.19% and return on invested capital (ROIC) is -87.73%.
| Return on Equity (ROE) | -195.19% |
| Return on Assets (ROA) | -62.31% |
| Return on Invested Capital (ROIC) | -87.73% |
| Return on Capital Employed (ROCE) | -236.40% |
| Weighted Average Cost of Capital (WACC) | 11.28% |
| Revenue Per Employee | $173,171 |
| Profits Per Employee | -$919,098 |
| Employee Count | 41 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.06% in the last 52 weeks. The beta is 1.50, so Cue Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.50 |
| 52-Week Price Change | -80.06% |
| 50-Day Moving Average | 0.35 |
| 200-Day Moving Average | 0.64 |
| Relative Strength Index (RSI) | 40.70 |
| Average Volume (20 Days) | 1,019,620 |
Short Selling Information
The latest short interest is 2.17 million, so 2.37% of the outstanding shares have been sold short.
| Short Interest | 2.17M |
| Short Previous Month | 1.85M |
| Short % of Shares Out | 2.37% |
| Short % of Float | 2.39% |
| Short Ratio (days to cover) | 1.14 |
Income Statement
In the last 12 months, Cue Biopharma had revenue of $7.10 million and -$37.68 million in losses. Loss per share was -$0.44.
| Revenue | 7.10M |
| Gross Profit | -28.33M |
| Operating Income | -38.11M |
| Pretax Income | -37.68M |
| Net Income | -37.68M |
| EBITDA | -37.73M |
| EBIT | -38.11M |
| Loss Per Share | -$0.44 |
Full Income StatementBalance Sheet
The company has $20.42 million in cash and $6.17 million in debt, with a net cash position of $14.25 million or $0.16 per share.
| Cash & Cash Equivalents | 20.42M |
| Total Debt | 6.17M |
| Net Cash | 14.25M |
| Net Cash Per Share | $0.16 |
| Equity (Book Value) | 13.25M |
| Book Value Per Share | 0.17 |
| Working Capital | 10.30M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$29.64 million and capital expenditures -$179,000, giving a free cash flow of -$29.82 million.
| Operating Cash Flow | -29.64M |
| Capital Expenditures | -179,000 |
| Free Cash Flow | -29.82M |
| FCF Per Share | -$0.33 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -536.73% |
| Pretax Margin | -530.75% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cue Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -74.30% |
| Shareholder Yield | -74.30% |
| Earnings Yield | -139.02% |
| FCF Yield | -110.00% |
Analyst Forecast
The average price target for Cue Biopharma is $3.00, which is 909.76% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 909.76% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | -30.91% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cue Biopharma has an Altman Z-Score of -17.56 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.56 |
| Piotroski F-Score | 2 |
